The incidence of allergic diseases has dramatically increased in recent decades, especially in urban and industrialized areas. It has been reported that, at present, one third of the population in Japan suffers from bronchial asthma, atopic dermatitis, or allergic rhinitis. The medical cost for treating such patients is huge and on the increase. Thus, it is important socially as well as medically to establish more useful strategies to overcome allergic disorders. Bronchial asthma is a complex disease characterized by airway inflammation involving a Th2-cytokine, interleukin (IL)-13. A substantial body of evidence has accumulated pointing to the pivotal role of IL-13 in the pathogenesis of bronchial asthma. Therefore, IL-13 and its signal pathway are thought to be promising targets to develop a therapeutic agent for bronchial asthma. In this article, we summarize the biological properties of IL-13 itself and its signal transduction pathway, the pathological roles of IL-13 in bronchial asthma, and the agents to inhibit the IL-13 signals that are now under development.
INTRODUCTION
The IL-13 and IL-4 genes, encoding two Th2-type cytokines, are assumed to evolve by the duplication of either gene. Additionally, IL-13 shares receptors and signal pathways with IL-4; therefore, IL-13 shows biological activities similar to IL-4. However, the importance of IL-13 in the pathogenesis of bronchial asthma has been recently demonstrated, indicating that IL-13 may have biological activities different from IL-4 in the body. Based on these findings, IL-13 has emerged as a promising target for allergic diseases.
IL-13
The cDNA encoding mouse IL-13 was originally identified as a highly expressed gene in a Th2-type cell line, C1.Ly-1 + 2 -/9, by a group at DNAX Research Institute, and it was denoted P600 with its biological activities unknown [1] . Thereafter, three independent groups identified human IL-13. One group identified human IL-13 from the library of human activated T cells based on information about the mouse IL-13 sequence [2] . They showed that its product induces expression of MHC class II antigen and CD23 in monocytes and proliferation co-operating with the stimulus by anti-IgM antibody (Ab) or anti-CD40 Ab in B cells. Another group found human IL-13 as a highly expressed gene in peripheral blood mononuclear cells stimulated by anti-CD28 Ab [3] . Its product causes anti-inflammatory actions on activated monocytes and induces production of IFN-in large granular lymphocytes. Furthermore, the other group determined the partial sequence of the IL-13 cDNA from the cDNA library of activated peripheral blood mononuclear cells using a genomic DNA containing the IL-4 and IL-5 genes as a probe [4] . It turned out that the molecules independently identified by the three groups are the same, and the name IL-13 was assigned.
Both IL13 and Il13 genes are about 4.5 kb in length and consist of four exons and three introns. The IL13 and Il13 genes locate at 5q31 and 29.0 cM on chromosome 11, respectively. Cytokine genes-IL-3, GM-CSF, IL-5, IL-13, IL-4 from the centromere to the teromere-form a cluster in these regions. The exon/intron structures of these cytokines are well conserved and are assumed to have arisen from a common ancestor gene [5] . The IL-13 and IL-4 genes are adjacent, with the distance between these two genes being only 12.5 kb. Between these two genes, there exist several DNA sequences conserved among mammals (conserved noncoding sequences: CNS), which are known to act as ciselements for the expression of these two genes, in other words, for the regulation of Th2-type immune responses [6] .
The human and mouse IL-13 proteins consist of 132 and 131 amino acids, respectively, showing 61.7% identity at the amino acid level. The human IL-13 includes a signal peptide of 20 amino acids in length, and its mobility on the SDS-PAGE gel is about 10 kDa. There is some reference predicting the length of the signal peptide as 18 amino acids [2] . However, it is assumed to be 20 amino acids, based on the N-terminal sequences of IL-13 that were forcibly expressed in yeasts and COS7 cells [7] . Although the amino acid sequence of human IL-13 contains four potential Nglycosylation sites, modification of IL-13 proteins by glycosylation did not occur, when it was expressed in COS7 cells [7] . The homology or identity of IL-13 with other cytokines in the primary structure is relatively low, and its identity with IL-4, the most evolutionarily closest cytokine, is about 25%. However, the steric structure of IL-13 is the same as that of the short chain cytokine family including IL-3, IL-4, IL-5, and GM-CSF, in that all of these cytokines show upup-down-down four-helix bundle topology [8, 9] (Fig. 1) .
Four cysteine residues in IL-13 form two intramolecular disulfide bindings. Many hydrophobic amino acids form the hydrophobic core inside the molecule, of which Leu16, Phe94, and Thr87 are conserved among the short chain cytokine family. It has been assumed that the binding site of IL-13 to IL-13R 1 is -helix A and -helix D, because -helix A and -helix D of IL-4 interact with either c or IL-13R 1, based on the structure of the IL-4/IL-4R complex [10] , and IL-13 has a significant similarity in folding topology to IL-4 [8, 9] . Consistent with this assumption, it has been demonstrated that several amino acid residues in -helix D of IL-13 (Lys90, Ile91, His 103 Leu104, Lys105, Lys106, Arg109, Glu110, and Arg112) are important for binding to IL-13R 1 and/or IL-13R 2, although -helix A of IL-13 is predicted to interact with IL-4R [11] [12] [13] . Glu11 of IL-13, a critical amino residue for its activity, is an acidic amino acid residue in -helix A conserved with many cytokines [14] .
THE IL-13 RECEPTOR AND ITS SIGNAL PA-THWAYS a. Overall view
The IL-13 receptor (IL-13R) is a heterodimer composed of the IL-13R 1 chain (IL-13R 1) and the IL-4R chain (IL-4R ), and it also acts as type II IL-4R [15, 16] (Fig. 2) . IL-13 binds to IL-13R 1 first with low affinity (Kd=2-10 nM), and then recruits IL-4R to the complex, generating a high-affinity receptor (Kd=0.03-0.4 nM) [17] [18] [19] . Heterodimerization of the IL-13R by IL-13 causes activation of the JAK/STAT and phosphatidylinositol-3 (PI-3) kinase pathways inside the cells as well as IL-4. In the JAK/STAT pathway, both TYK2 and JAK1 are first activated, followed by activation of STAT6 and STAT3. Because both IL-13 and IL-4 activate STAT6, these two cytokines exert similar biological activities. STAT6 is a transcription factor, critical for both the IL-13 and IL-4 signals, as described later. The STAT3-STAT1 pathway has been implicated, together with STAT6, in the induction of 15-lipoxygenase in human monocytes [20] . Insulin receptor substrate (IRS) is a linker protein for PI-3 kinase to associate with tyrosine-phosphorylated IL-4R . IRS-2 is involved in Th2 cell differentiation [21, 22] . There is another IL-13 binding unit, the IL-13R 2 chain (IL-13R 2), which binds to IL-13 with high affinity (0.25-1.2 nM; Fig. 2) [23, 24] . However, as the intracellular domain of IL-13R 2 is short, and does not contain the Box1 motif, an important domain for intracellular signaling, IL-13R 2 does not associate with signaling molecules, acting instead as a "decoy" receptor.
b. IL-4R
Human and mouse IL-4R consist of 825 and 810 amino acids, respectively, including signal peptides, and these two molecules show 53.0% identity at the amino acid level [25] [26] [27] [28] . The IL4RA and Il4ra genes locate at the chromosome 16p11.2-12.1 and at 762.0 cM on chromosome 7, respectively. The soluble IL-4R is generated by alternative splicing or membrane shedding in addition to the membrane form [29, 30] . IL-4R belongs to the type I cytokine receptor family, and there exist four conserved cysteine residues and the WSXWS motif in its extracellular domain. The extracellular domain of IL-4R is composed of two fibronectin III domains that comprise the cytokine receptor homology module (CRH), a common structure of the class I cytokine receptor superfamily [31] , and does not possess an extra fibronectin III domain like IL-13R 1 or IL-13R 2. The intracellular domain of IL-4R possesses several domains important for signal transduction-the Box1 region, the ID-1 domain, the I4R motif, tyrosine residues (Tyr550, Tyr576, and Tyr606), and the ITIM motif.
(1) Box 1 region (262-269 amino acid from the starting point) [32] : The WWDXIPXP sequence fits the characteristic of Box 1 motif, and this domain is known to bind to JAK1.
(2) ID-1 region (353-393 amino acid from the starting point) [33] [34] [35] [36] : This region is rich in glutamic acid, and is not homologous with any known molecule. This region is necessary for the proliferation signal, expression of germline transcript, and activation of STAT6.
(3) I4R region (488-502 amino acid from the starting point) [37] [38] [39] [40] [41] : This region is so named because this motif is shared by the insulin receptor and IL-4R . This region is required for activation of both JAK3 and STAT6, tyrosine phosphorylation of IRS1-4, the proliferation signal, and the anti-apoptosis effect. Particularly, tyrosine residue at 472 is critical in this region.
(4) Tyr550, Tyr576, and Tyr606 [38, 42, 43] : Three tyrosine residues at 550, 576, and 606, located in the membranedistal portion, are important for activation of STAT6, and these are probably binding sites of STAT6. If any of these three tyrosine residues remains, STAT6 is activated; however, when all three tyrosine residues are mutated, activation of STAT6 is abolished, followed by suppression of CD23, MHC class II, and germline expression. Because IL-4R is the common component of the IL-4R and IL-13R, important for both IL-4 and IL-13 signals, IL-4R knockout mice show severe impairment of the defense system against parasites, compared to either IL-4 or IL-13 knockout mice [45, 46] . IL-4R is constitutively expressed in the bronchial tissues such as bronchial epithelial cells and bronchial smooth muscle cells [47] , and the stimulus of either IL-4 or IL-13 affects the expression of IL-4R .
c. IL-13R 1
Human and mouse IL-13R 1 consist of 427 and 424 amino acids, respectively, including signal peptides, and these two molecules show 77.0% identity at the amino acid level [17, 48] . The IL13RA1 and Il13ra1 genes locate at the chromosome Xq24 and at 12.5 cM on chromosome X, respectively. The soluble IL-13R 1 is generated by alternative splicing as well as IL-4R [49] .
Extracellular portions of IL-13R 1 are composed of three fibronectin III domains-D1, D2, and D3-of which the latter two comprise CRH (Fig. 1) . By incorporating mutations into these amino acids, we identified Leu319 and Tyr321 in the CRH of human IL-13R 1, as critical residues for binding to IL-13 [50] . Furthermore, we found that the D1 domain, an extra fibronectin III domain, is important for binding to IL-13, but not to IL-4. Four positionally conserved cysteine residues in the D2 domain form two disulfide bonds, and a WSXWS sequence locates in the F'-G' loop in the D3 domain, both of which are critical for the receptors to position correctly and bind to ligands [31] . The IL-13/IL-13R 1/IL-4R complex may generate the hexametric receptor complex, like the IL-6/IL-6R /gp130, in which the D1 domain of gp130 has a bridging function, interacting with the binding epitope on IL-6 in the opposite trimer [51, 52] .
The intracellular domain of IL-13R 1 possesses the Box1 motif in the proximal region to the transmembrane domain binding to TYK2, and tyrosine residues binding to STAT3 [53, 54] . IL-13R 1 is ubiquitously expressed in many tissues [17, 48, 55, 56] . Very little of IL-13R 1 is expressed in the resting stage of B cells, so that IL-13 signals are weakly transduced, whereas either anti-IgM Ab or anti-CD 40 Ab upregulates expression of IL-13R 1, letting more IL-13 signals be transduced intracellularly [54, 57] . In the bronchial tissues, IL-13R 1 is constitutively expressed on bronchial epithelial cells and bronchial smooth muscle cells, and the stimulus of either IL-4 or IL-13 affects its expression as well as IL-4R [47] .
d. IL-13R 2
Human and mouse IL-13R 2 are composed of 380 and 383 amino acids, respectively, including signal peptides, and these two molecules show 60.8% identity at the amino acid level [23, 24] . The IL13RA2 and Il13ra2 genes locate at the chromosome Xq13.1-28 and at 63.0 cM on the chromosome X, respectively. The soluble IL-13R 2 is generated by alternative splicing as well as IL-13R 1 and IL-4R [58] .
The extracellular domain of IL-13R 2 is composed of D1, D2, and D3, of which the latter two comprise CRH as well as IL-13R 1. By incorporating mutations into these amino acids, we identified Tyr207, Asp271, Tyr315, and Asp318 in the CRH, as critical residues for binding to IL-13 [50] . Tyr315 in IL-13R 2 and Leu319 in IL-13R 1 are positionally conserved hydrophobic amino acid residues. The D1 domain is needed for the expression of IL-13R 2. There exist four positionally conserved cysteine residues in the D2 domain forming two disulfide bonds, and a WSXWS se- quence locates in the F'-G' loop in the D3 domain, characteristic for the type I cytokine receptor family [31] .
The intracellular domain of IL-13R 2 is short, 17 amino acids in length, and does not possess the Box1 motif. When IL-13R 2 is expressed in human bronchial epithelial cells, activation of STAT6 by IL-4 or IL-13 is blocked, demonstrating that IL-13R 2 acts as a "decoy" receptor [59] [60] [61] . Furthermore, upon stimulation of IL-4 or IL-13, IL-13R 2 is expressed in bronchial epithelial cells and hepatocytes, indicating that this induction of IL-13R 2 by IL-4 or IL-13 has a role in a negative-feedback system for IL-13 signals [61] [62] [63] .
e. STAT6
Human and mouse STAT6 are comprised of 847 and 837 amino acids, respectively, and these two molecules show 84.2% homology at the amino acid level [38, 42] . The STAT6 and Stat6 genes locate at the chromosome 12q13 and at 70.0 cM on the chromosome 10, respectively.
STAT6 has a coiled-coil domain in its N terminus, a DNA-binding domain, a linker domain, and an SH2 domain in its middle, and a transactivation domain in its C terminus. Tyr641 in the SH2 domain is phosphorylated by binding of the ligand to the receptor, and its phosphorylation is critical for DNA binding of STAT6 [64] . Thr645 close to Tyr641 is a negative regulatory site for activation of STAT6, and protein phosphatase 2A dephosphorylates phosphorylated Thr645, followed by activation of STAT6. Ser756 in the transactivation domain is phosphorylated by binding of the ligand to the receptor, with its role uncertain.
Analyses of STAT6 knockout mice have shown that STAT6 is critical for both IL-4 and IL-13 signals [65] [66] [67] [68] . Disruption of STAT6 also causes abrogation of airway hyperresponsiveness in asthma-model mice [69] , although it is controversial, in that there is a reference that asthmatic phenotypes are less impaired in STAT6 knockout mice than IL-4/IL-13 double knockout mice [70] .
SINGLE NUCLEOTIDE POLYMORPHISMS OF IL-13 SIGNALING MOLECULES AND ITS CORRELA-TION WITH ALLERGIC DISEASES
Thus far, it is known that there exist at least nine single nucleotide polymorphisms (SNPs) on the IL13 gene, and that all SNPs except those locating in the 5'-untranslated region are in linkage disequilibrium (Fig. 3) . We found a polymorphism in exon 4 on the IL-13 gene, which causes the exchange of arginine at the 110 amino acid from the start of the mature protein (Arg110) for glutamine (Gln110). The incidence of Gln110 was higher than Arg110 in asthmatic patients of both Japanese and British populations [47] . These results demonstrated that this variant was genetically correlated with bronchial asthma. We next compared the function of Gln110 and Arg110 [71] . Gln110 showed lower affinity with IL-13R 2, the decoy receptor for IL-13, than Arg110, whereas both Gln110 and Arg110 showed the same affinity with the IL-13R 1/IL-4R complex. Furthermore, Gln110 showed enhanced stability compared to Arg110. Taking these results together, it is assumed that Gln110 up-regulates concentrations of IL-13 in the body and transduces stronger signals compared to Arg110, which would contribute to the onset or exacerbation of bronchial asthma. In fact, several groups thereafter reported a genetic correlation between this variant and serum total IgE, or atopic dermatitis, or the positive test for antigen-specific RAST in German, American, and Chinese populations [72] [73] [74] . Furthermore, two groups published functional analyses about this variant [75, 76] . Both demonstrated that Gln110 transduces stronger signals the IL-13R 1/IL-4R complex than Arg110. Furthermore, Chen et al. reported that Gln110 causes airway hyperresponsiveness in mice more than Arg110, and Vladich et al. showed that Gln110 generates more IgE than Arg110 in the presence of steroids. It is of note that Chen et al. demonstrated that Gln110 of IL-13 showed enhancement of IL-13 signals, co-operating with the variant of IL-4R (Val50Arg551), which had been shown to increase the IL-4 signals [77, 78] . Although the details of the results found by these three groups including ours are different, all of these analyses supported the notion that this variant up-regulates the IL-13 signals in the body.
In addition to Gln110Arg, the variant, -1111(-1055)C/T on the IL13 gene, has been shown to be genetically correlated with allergic bronchial asthma and positive skin test [79, 80] . This SNP is adjacent to the binding site for NFAT; hence, this variant may affect the complex formation of transcription factors. The variant, 4738G/A on the IL13 gene, is demonstrated to be correlated with bronchial asthma, atopic dermatitis, and positive skin test [80] . Additionally, it has been reported that the variants, A1398G on the IL13RA1 gene, and several polymorphisms on the STAT6 gene, are genetically correlated with serum total IgE in Caucasian populations [47, 81, 82] . These variants may affect the IL-13 signals.
EXPRESSION OF IL-13
Cells that are ascertained to express IL-13 are CD4 + T cells, mast cells, basophils, eosinophils, and NKT cells [5, 83, 84] . Th2-type cells among CD4 + T cells secrete IL-13, which is why IL-13 belongs to the Th2-type cytokines, as do IL-4, IL-5, IL-9, and IL-10.
GATA3 is critical for expression of IL-13, as well as other Th-2 type cytokines such as IL-4 and IL-5. It has been confirmed by the finding that expression of IL-4, IL-5, and IL-13 is down-regulated in non-functional GATA3-expressing mice [85] . A GATA3-responsive element (CGRE), the binding site to GATA3, locates 1.6 kbp upstream of the IL13 gene, to which histone acetyltransferase, CBP/p300, and RNA polymerase II bind together with GATA3, leading to Th-2 cell-specific histone acetylation, followed by expression of the IL13 gene [86] . Furthermore, activation of both NF-B and STAT6 is also required for expression of GA-TA3 [86, 87] . Involvement of NFAT1 in expression of IL-13 has been demonstrated by analyses using Jurkat cells and mouse mast cells [88, 89] . In contrast to GATA3, expression of IL-13 does not need c-Maf, which is required for expression of IL-4 [90] .
IL-13 actions
Human IL-13 causes immunoglobulin class switching to IgE and IgG4, upregulation of CD23 and MHC class II antigen in B cells and exerts anti-inflammatory actions in monocytes [5] . However, in contrast to IL-4, IL-13 does not cause proliferation of T cells or differentiation of naive T cells towards Th2 cells. Activation of mast cells by IL-13 is weaker than by IL-4. Although it had been thought that mouse IL-13 does not act on B cells in in vitro systems [5] , it has been demonstrated that IL-13 contributes to IgE synthesis in vivo [91, 92] . Furthermore, it has been indicated that there exists an IL-4/IL-13-independent pathway for IgE synthesis [93, 94] . Mouse IL-13 causes anti-inflammation as well as human IL-13 on monocytes.
Following the analyses of IL-13 actions on immune cells, those on non-immune cells have been focused. Particularly, considering the involvement of IL-13 in the pathogenesis of bronchial asthma, IL-13 actions on resident cells in the bronchial tissues have been well characterized. It has been shown that IL-13 induces production of TGF- [95, 96] , eotaxin-3 [97] , and mucin [98] , and induction of human calciumactivated chloride channel 1 (hCLCA1) or mCLCA3 (Gob-5) [99, 100] in bronchial epithelial cells. IL-13 also acts on fibroblasts, inducing expression of integrins [101] and periostin [102] and proliferation [103] . Furthermore, IL-13 induces production of eotaxin [104, 105] and enhances contractility [106, 107] in bronchial smooth muscle cells. Thus, IL-13 has diverse activities for non-immune cells.
We have identified that IL-4 or IL-13 induced expression of squamous cell carcinoma cell antigen 1 (SCCA1; SER-PINB3) and SCCA2 (SERPINB4) belonging to the ovalbumin-serpin family, in bronchial epithelial cells by microarray approach [108] . Serum SCCA level is high in asthmatic children, indicating that it is a novel biomarker for bronchial asthma [108, 109] . Because SCCA1 and SCCA2 inhibits not only intrinsic proteinase, but also extrinsic proteinase including major mite allergens, Der p 1 and Der f 1, these molecules would act as effectors of the defense mechanism of IL-4 and/or IL-13 against microbes [110, 111] .
Involvement of IL-13 in the pathogenesis of bronchial asthma
A substantial body of evidence using asthma-model mice has shown that IL-13 has a pivotal role in generating bronchial asthma [112] [113] [114] [115] . It has been also demonstrated that expression of IL-13 is high in the lesions of bronchial asthma [116] [117] [118] [119] . Furthermore, the correlation between SNPs on the IL13 gene and genes encoding its signaling molecules and allergic diseases, including bronchial asthma, has been pointed out as described earlier. These results strongly suggest that IL-13 also has a pivotal role in the pathogenesis of human bronchial asthma.
It has been puzzling that although IL-13 and IL-4 transduce their signals through the common receptor, IL-13R/type II IL-4R, asthmatic phenotypes caused by IL-13 are more significant than IL-4 [112, 113, 120, 121] . In other words, IL-13 is a more attractive target to improve or cure bronchial asthma than IL-4. However, the precise mechanism of this discrepancy remains unclear. It has been recently reported that IL-4, but not IL-13, induces IL-12 in dendritic cells type I IL-4R, followed by IFN-production in lung tissues, which would inhibit proasthmatic signals of IL-4 or IL-13 IL-13R/type II IL-4R [122] .
It had been believed that IL-13 was involved in causing allergic diseases by inducing IgE in B cells. However, analyses of model mice with bronchial asthma suggested that blockage of IL-13 inhibits airway hyperresponsiveness and mucus production, but not IgE production or eosinophilic infiltration [112, 113] . Furthermore, such inhibitory actions of IL-13 on asthmatic phenotypes are independent of lymphocytes, as revealed by using RAG1 knockout mice. Together, these results demonstrate that IL-13 acts on resident cells in the bronchial tissues, inducing asthmatic phenotypes. This notion is supported by the analyses of transgenic mice in which IL-13 is specifically expressed in bronchial epithelial cells [114] and of STAT6 knockout mice in which expression of STAT6 is recovered only in bronchial epithelial cells [115] . Furthermore, human bronchial epithelial cells cultured in an air-liquid interface system in the presence of IL-13 showed goblet cell metaplasia [123] . Analyses to clarify precisely how IL-13 causes asthmatic phenotypes have been conducted by several different groups, and several molecules downstream of IL-13 signals involved in the pathogenesis of bronchial asthma have been highlighted.
a. hCLCA1 or mCLCA3 (Gob-5)
Nakanishi et al. identified mCLCA3 (Gob-5) as an induced gene in ovalbumin-induced asthma mice [124] . Expression of mCLCA3 was correlated with mucus production and airway hyperresponsiveness. The human orthologue of mCLCA3, hCLCA1, was highly expressed in bronchial lesions of asthma patients [125] . It has been demonstrated that either IL-9 or IL-13 induces expression of mCLCA3 or hCLCA1 [99, 100, 125] . However, the analyses of mCLCA3 knockout mice showed almost normal phenotypes, indicating the redundancy of molecules related to mCLCA3 [126] . It had been thought that mCLCA3 or hCLCA1 acted as a membrane-embedded chloride channel [124] . However, it has turned out that mCLCA3 and hCLCA1 are secreted proteins [127] . Further studies are needed to elucidate the function of mCLCA3 and hCLCA1.
b. Chitinase
Zhu et al. demonstrated that chitinase is induced in epithelial cells and macrophages of bronchial asthma-induced mice in an IL-13-dependent manner, and that chitinase would act as a modulator of Th2 inflammation [128] . The precise mechanism of involvement of chitinase in Th2 inflammation remains obscure. Chitin is a major component of parasites; therefore, chitinase induced by IL-13 would act as a defense mechanism against parasites.
c. Periostin
We previously identified the POSTN gene encoding periostin as one of the IL-4/IL-13-inducible gene in bronchial epithelial cells by microarray analysis [108] . Periostin is thought to be an adhesion molecule as it possesses four fasciclin I domains in its middle. Therefore, we explored the possibility that periostin is involved in subepithelial fibrosis of bronchial asthma [102] . Both IL-4 and IL-13 induced secretion of periostin in lung fibroblasts independently of TGF-. Periostin co-localized with other extracellular matrix proteins involved in subepithelial fibrosis thickening in both asthma patients and asthma-induced wild mice, but not in either IL-4 or IL-13 knockout mice. Periostin had an ability to bind to fibronectin, tenascin-C, collagen V, and periostin itself. Taking these results together suggests that periostin, secreted from lung fibroblasts by IL-4 and/or IL-13, is involved in subepithelial fibrosis of bronchial asthma, interacting with other extracellular matrix proteins.
NEW AGENTS TARGETING IL-13 FOR BRON-CHIAL ASTHMA
Because IL-13 is thought to be the central mediator of the effector phase of bronchial asthma, it is reasoned that blocking the biological activities of IL-13 should be a good strategy to improve asthmatic status. The following agents targeting IL-13 have been announced to be under development ( Table 1) .
a. Soluble IL-13R
The strategy to improve bronchial asthma by a soluble cytokine receptor was first applied to soluble IL-4R [129, 130] . Such a strategy has the advantage of avoiding immunogenicity, compared to a neutralizing antibody or a variant protein. Following the analyses using model mice, soluble recombinant IL-13R has also been tested as an agent curing bronchial asthma as well as soluble IL-4R . Two candidates of soluble IL-13R exist; one is soluble IL-13R 1 and the other is IL-13R 2. Because the affinity of IL-13R 2 with IL-13 (Kd=0.25-1.2 nM) is more than 10-fold higher than that of IL-13R 1 (Kd=2-10 nM), soluble IL-13R 2 has a superior potency as a blocking agent [18, 23, 71] . Wyeth is developing soluble IL-13R 2 as a novel product, and they report that it was effective for decreasing airway hyperresponsiveness in bronchial asthma-inducing mice and guinea 
b. IL-4 mutein
IL-4 mutein is listed as another IL-13 antagonist. IL-4 muteins in this context indicate two types of IL-4 variants whose tyrosine at 124 is replaced with aspartate (Y124D), and arginine at 121 is furthermore replaced with aspartate (R121D/Y124D) [133] [134] [135] . These muteins act as antagonists for both IL-4 and IL-13, because those are able to bind to the IL-4R/IL-13R, but not able to transduce the signal. Bayer Inc. had developed R121D/Y124D as a therapeutic agent for bronchial asthma (pitrakinra, BY-16-9996) and had gone on to phase 2 clinical trials. AEROVANCE Inc., under license from Bayer, is developing the same reagent, now denoted AEROVANT TM , as a therapeutic agent for bronchial asthma in a phase 2a study (http://www.aerovance.com/index.html).
c. Anti-IL-13 Ab and Anti-IL-13R 1 Ab
It has been shown that pretreatment with anti-IL-13 Ab (CAT-354) significantly decreases airway hyperresponsiveness and eosinophilia induced by IL-13 [136] . Cambridge Antibody Technology has announced preliminary results of a phase 1 clinical trial of anti-IL-13 monoclonal Ab to treatment for severe asthma, showing that it well tolerated with no safety concerns identified (http://www.cambridgeantibody.com/html/technology_products/product_pipeline/cat35 4). AMRAD Corp. is now developing anti-IL-13R 1 Ab as a therapeutic agent for allergic diseases, and has announced that formal preclinical studies have begun (http://www. amrad.com.au/Files/IL-13a1.pdf).
CONCLUSIONS
The biological properties of IL-13 itself and its signal transduction pathways have been well characterized. Furthermore, pivotal roles of IL-13 in the pathogenesis of bronchial asthma have been established, although precise molecular mechanisms have remained undetermined. It is hoped that a therapeutic agent for bronchial asthma aiming to block actions of IL-13 or its signal pathways will be developed in the near future.
